| TXN |
Report |
Revenue |
BEAT |
pred ~$5.30B vs. cons $5.21B |
MEDIUM |
| TXN |
Report |
EPS |
BEAT |
pred ~$2.01 vs. cons $1.92 |
MEDIUM |
| TXN |
Report |
Gross margin |
IN-LINE |
pred ~60.0% vs. cons 59.6% |
MEDIUM |
| TXN |
Guide |
Revenue guidance |
BETTER |
guide ~$5.35B vs. cons $5.30B (2026Q3) |
MEDIUM |
| TXN |
Guide |
EPS guidance |
BETTER |
guide ~$2.02 vs. cons $1.99 (2026Q3) |
LOW |
| TXN |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.8% |
— |
MEDIUM |
| TXN |
Return |
5-day cumulative residual |
+1.4% (FADE) |
A modest Q3 revenue and EPS raise should lift near-term estimates, but limited out-period revision, cautious second-half language and the demanding valuation setup are likely to fade part of the initial beat-driven gain. |
MEDIUM |